Erytech Pharma
ERYP.PADrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
GRASPA
Acute Lymphoblastic Leukemia, in Relapse
eryaspase
Pancreatic Adenocarcinoma
native L asparaginase
Acute Lymphoblastic Leukemia
ERY001
Pancreatic Adenocarcinoma Metastatic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GRASPA | Phase 3 | Acute Lymphoblastic Leukemia, in Relapse | - | - |
eryaspase | Phase 3 | Pancreatic Adenocarcinoma | - | - |
native L asparaginase | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
ERY001 | Phase 2 | Pancreatic Adenocarcinoma Metastatic | - | - |
Frequently asked questions
What is in Erytech Pharma's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Erytech Pharma's (ERYP.PA) pipeline across Phase 3, Phase 2. Its lead program is GRASPA (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Erytech Pharma's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Erytech Pharma (ERYP.PA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ERYP.PA biotech catalysts?→
Add ERYP.PA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Erytech Pharma's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.